Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Poonam Pegu"'
Autor:
Piyathida Sroysuwan, Natthapol Kosashunhanan, Sebastian Molnar, Jerome H. Kim, Alexandra Schuetz, Taweewat Supindham, Elizabeth Heger, Sandhya Vasan, Phiromrat Rakyat, Suwat Chariyalertsak, Nittaya Phanuphak, Siriluck Teerachia, Suchada Chinaworapong, Nongluck Sangnoi, Oranitcha Kaewthip, Sorachai Nitayaphan, Surat Jongrakthaitae, Pornchanok Panjapornsuk, Michael A. Eller, Puttachard Saengtawan, Weerawan Chuenarom, Nuntisa Chotirosniramit, Pornsuk V. Grandin, Sirinan Madnote, Benjaluck Phonrat, Rungsun Rerknimitr, Narongrid Sirisopana, Lindsay Wieczorek, Siriwat Akapirat, Chirapa Eamsila, Faruk Sinangil, Kirsten Smith, James Tartaglia, Poonam Pegu, Dohoon Kim, Carter Lee, Peter Dawson, Saowanit Getchalarat, Robert J. O'Connell, Nicos Karasavvas, Jiraporn Puangkaew, Patcharaphan Sugandhavesa, Nitiya Chomchey, Punnee Pitisuttithum, Jean-Louis Excler, Boonlure Pruenglampoo, Yingjun Zhou, Yupa Sabmee, Jittima Dhitavat, Merlin L. Robb, Jesse Schoen, Victoria R. Polonis, Nelson L. Michael, Boot Kaewboon, Nipat Teeratakulpisarn, Bessara Nuntapinit, Wanlaya Labwech, Eugene Kroon, Viseth Ngauy, Prapaporn Savaraj, Jaranit Kaewkungwal, Pawinee Jarujareet, Nampueng Churikanont, Surawach Rittiroongrad, Somsak Chantakulkij, Anant Phramtong, Rapee Trichavaroj, Carlos A. DiazGranados, Silvia Ratto-Kim, Sanjay Phogat, Mark de Souza, Arom Pitisuthitham, Nipattra Tragonlugsana
Publikováno v:
Lancet HIV
BACKGROUND: The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX® B/E administration over six months resulted in a 31% efficacy in preventing HIV acquisition. In this trial, we assessed the immunologic impact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f962459539bb0b1f931c1b9f15f516
https://europepmc.org/articles/PMC7247755/
https://europepmc.org/articles/PMC7247755/
Autor:
Poonam Pegu, Julie Dorsey-Spitz, Merlin L. Robb, Bernard Moss, Hannah Kibuuka, Nicos Karasavva, Silvia Ratto-Kim, David B. Weiner, Marco Missanga, P. Mann, Alexandra Schuetz, Josphat Kosgei, Mark Milazzo, G Laissa Ouedraogo, A Sekiziyivu, Niranjan Y. Sardesai, Sheila A. Peel, Lindsay Wieczorek, Jian Yan, Patricia L. Earl, Michael A. Eller, Arne Kroidl, Leonard Maboko, Nelson L. Michael, Fredrick Sawe, Victoria R. Polonis, Leigh Anne Eller, Viseth Ngauy, Julie A Ake, Farrukh Rizvi, Amir S. Khan, Mary A. Marovich
Publikováno v:
The Journal of Infectious Diseases. 216:1080-1090
Background. We report the first-in-human safety and immunogenicity evaluation of PENNVAX-G DNA/modified vaccinia Ankara-Chiang Mai double recombinant (MVA-CMDR) prime-boost human immuonodeficiency virus (HIV) vaccine, with intramuscular DNA delivery
Autor:
Jaranit Kaewkungwal, Saintedym Wills, Carlos A. DiazGranados, Merlin L. Robb, Poonam Pegu, James Tartaglia, Rv Study Team, Allan C. deCamp, Nakorn Premsri, Alexandra Schuetz, Sanjay Garunathan, Michael A. Eller, Robert J. O'Connell, Nicos Karasavvas, Nathan Vandergrift, Sorachai Nitayaphan, Faruk Sinangil, Jean-Louis Excler, Punnee Pitisuttithum, Chitraporn Karnasuta, Nelson L. Michael, Silvia Ratto-Kim, Georgia D. Tomaras, Sanjay Phogat, Jerome H. Kim, Supachai Rerks-Ngarm, Sheetal Sawant, David C. Montefiori, Prayura Kunasol, Viseth Ngauy, Sandhya Vasan, Peter Dawson
Publikováno v:
The Journal of Infectious Diseases. 215:1255-1263
Background The RV144 ALVAC-HIV prime, AIDSVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acquisition at 1 year, waning to 31.2% after 3.5 years. We hypothesized that additional vaccinations might augment immune correla
Autor:
Peter Dawson, Jaranit Kaewkungwal, Faruk Sinangil, Elizabeth Heger, Lindsay Wieczorek, James Tartaglia, Punnee Pitisuttithum, Rv Study Team, Alexandra Schuetz, Sanjay Phogat, Carlos A. DiazGranados, Suwat Chariyalertsak, Nelson L. Michael, Kirsten S. Smith, Merlin L. Robb, Jerome H. Kim, Victoria R. Polonis, Siriwat Akapirat, Benjaluck Phonrat, Surat Jongrakthaitae, Sandhya Vasan, Michael A. Eller, Yingjun Zhou, Dohoon Kim, Robert J. O'Connell, Nicos Karasavvas, Jittima Dhitavat, Jean-Louis Excler, Sorachai Nitayapha, Poonam Pegu
Publikováno v:
SSRN Electronic Journal.
Background: The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX® B/E administration over six months resulted in a 31% efficacy in preventing HIV acquisition. Subsequent boosting of RV144 vaccine recipients 6
Autor:
Maria G. Pau, Peter Abbink, Lauren Peter, Nelson L. Michael, Michael S. Seaman, Hung V. Trinh, Joseph P. Nkolola, Poonam Pegu, Frank Tomaka, Dan H. Barouch, Katleen Callewaert, Julie A Ake, Merlin L. Robb, Jane A. Kleinjan, Rachel D Filter, Mangala Rao, Lindsey R. Baden, Jon A Gothing, Yehuda Z. Cohen, Steven Nijs, Stephen R. Walsh, Bette T. Korber, Jenny Hendriks, J. Humberto Licona, Patricia L. Earl, Bernard Moss, Hanneke Schuitemaker, Galit Alter, Erica N. Borducchi, Michael A. Eller, Michal Sarnecki, Jennifer Johnson, Julia Jennings, Marinela Kirilova, Ipcavd, Raphael Dolin, Kathryn E. Stephenson
Publikováno v:
Journal of infectious diseases, 218(4), 633-644. Oxford University Press
BACKGROUND: Mosaic immunogens are bioinformatically engineered human immunodeficiency virus type 1 (HIV-1) sequences designed to elicit clade-independent coverage against globally circulating HIV-1 strains. METHODS: This phase 1, double-blinded, rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21de4b0ba9357516e8ba840c8c396e0a
https://pure.amc.nl/en/publications/firstinhuman-randomized-controlled-trial-of-mosaic-hiv1-immunogens-delivered-via-a-modified-vaccinia-ankara-vector(df17a44b-2585-4618-9b64-1a793806e204).html
https://pure.amc.nl/en/publications/firstinhuman-randomized-controlled-trial-of-mosaic-hiv1-immunogens-delivered-via-a-modified-vaccinia-ankara-vector(df17a44b-2585-4618-9b64-1a793806e204).html
Autor:
Guido Ferrari, Shari N. Gordon, Barney S. Graham, Melvin N. Doster, Christopher B. Buck, David C. Montefiori, Michael Piatak, Poonam Pegu, Douglas R. Lowy, Jeffrey D. Lifson, Namal P.M. Liyanage, David Venzon, Monica Vaccari, Nicolas Çuburu, Marjorie Robert-Guroff, Brandon F. Keele, Anastasia Xenophontos, Egidio Brocca-Cofano, John T. Schiller, Rhonda C. Kines, Genoveffa Franchini, Yongjun Guan
Publikováno v:
The Journal of Immunology. 193:6172-6183
The human papillomavirus pseudovirions (HPV-PsVs) approach is an effective gene-delivery system that can prime or boost an immune response in the vaginal tract of nonhuman primates and mice. Intravaginal vaccination with HPV-PsVs expressing SIV genes
Autor:
Steven G. Reed, Blake Frey, Jay A. Berzofsky, Viraj Kulkarni, Diego A. Vargas-Inchaustegui, Thorsten Demberg, L. Jean Patterson, George N. Pavlakis, Yongjun Sui, Marjorie Robert-Guroff, Antonio Valentin, Shari N. Gordon, Margherita Rosati, Iskra Tuero, Barbara K. Felber, Janet DiPasquale, Genoveffa Franchini, David C. Montefiori, Candido Alicea, Poonam Pegu, David Venzon, Thomas Musich, Niranjan Y. Sardesai, Yichuan Wang, Venkatramanan Mohanram, Guy R. Pilkington, Jenifer Bear, Namal P.M. Liyanage, Alison Hogg
Publikováno v:
Clinical Immunology. 153:308-322
Combinatorial HIV/SIV vaccine approaches targeting multiple arms of the immune system might improve protective efficacy. We compared SIV-specific humoral immunity induced in rhesus macaques by five vaccine regimens. Systemic regimens included ALVAC-S
Autor:
Monica Vaccari, Genoveffa Franchini, Luca Schifanella, Danuta Lipinska, Melvin N. Doster, Nebiyu Shukur, Marcin Moniuszko, Cynthia A. Pise-Masison, Kamil Grubczak, Poonam Pegu, Namal P.M. Liyanage, Shari N. Gordon
Publikováno v:
Virology. :359-368
We characterized three subsets of NK cells in blood, and two subsets in mucosal tissues. SIVmac251 infection increased total and CD16+ NK cells in the blood. In the rectum, we observed a significant increase in total and NKG2A+ NK cells during SIV in
Autor:
Ranajit Pal, Poonam Pegu, Georgia D. Tomaras, Guido Ferrari, Nelson L. Michael, Yongjun Guan, Mangala Rao, Monica Vaccari, Jeffrey D. Lifson, Jim Tartaglia, David Venzon, Jerome H. Kim, Maria Grazia Ferrari, S. Munir Alam, Melvin N. Doster, Brandon F. Keele, Lauren Hudacik, Shari N. Gordon, David C. Montefiori, Claudio Fenizia, Erik Billings, Genoveffa Franchini, Stephen Whitney, Donald Stablein
Publikováno v:
Journal of Virology. 87:1708-1719
The recombinant canarypox vector, ALVAC-HIV, together with human immunodeficiency virus (HIV) gp120 envelope glycoprotein, has protected 31.2% of Thai individuals from HIV acquisition in the RV144 HIV vaccine trial. This outcome was unexpected, given
Autor:
Marjorie Robert-Guroff, Monica Vaccari, Xiaoying Shen, Guido Ferrari, Wenlei Zhang, Jennifer Schwartz, Mangala Rao, Namal P.M. Liyanage, Kathryn E. Foulds, Donald Stablein, Tran B. Phan, Shari N. Gordon, Poonam Pegu, Erik Billings, Mario Roederer, Kathryn Bobb, Donald N. Forthal, Sanjay Phogat, Ilia Prado, Diego A. Vargas-Inchaustegui, Genoveffa Franchini, Georgia D. Tomaras, David Venzon, Melvin N. Doster, David C. Montefiori, Timothy R. Fouts, Luca Schifanella
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950), vol 197, iss 7
The recombinant ALVAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SIV acquisition. Ab responses to the V1/V2 regions have correlated with a decreased risk of virus acquisition in both humans and macaques.